X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Nicole Longo

Nicole Longo Nicole is senior director of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.

Recent Posts

Word of the Month: 340B covered entity

By Nicole Longo  |    August 29, 2022
What is a 340B covered entity?   Read More

This week’s reading list: All the reasons the Senate-passed drug pricing bill is bad policy

By Nicole Longo  |    August 10, 2022
Last weekend, the Senate passed the Inflation Reduction Act which includes dangerous price-setting provisions. The bill now heads to the House for consideration, where it is not too late for them to...   Read More

Myth vs. Fact: The Senate’s latest price setting proposal

By Nicole Longo  |    August 5, 2022
The narratives being built around the Senate’s latest price setting proposal frame it as a bill intended to lower drug prices for patients and address rising inflation. But those narratives aren’t...   Read More

The Senate’s latest price setting proposal will undermine U.S. economic growth

By Nicole Longo  |    August 3, 2022
Last week, we examined ways the latest drug pricing proposal will undermine patient access to medicines, American medical innovation and our health care system as a whole. But there is another...   Read More

The Senate’s latest price setting proposal will undermine: Our health care system

By Nicole Longo  |    July 28, 2022
Members of Congress continue to push a misguided drug pricing proposal under the guise of negotiation as part of the reconciliation package. This proposal is nothing short of government price setting...   Read More

The Senate’s latest price setting proposal will undermine: American medical innovation

By Nicole Longo  |    July 27, 2022
Members of Congress continue to push a misguided drug pricing proposal under the guise of negotiation as part of the reconciliation package. This proposal is nothing short of government price setting...   Read More

The Senate’s latest price setting proposal will undermine: Patient access to medicines

By Nicole Longo  |    July 26, 2022
Members of Congress continue to push a misguided drug pricing proposal under the guise of negotiation as part of the reconciliation package. This proposal is nothing short of government price setting...   Read More

By the Numbers: Patients lose when the government sets prices

By Nicole Longo  |    July 8, 2022
Yet again, Congress is considering harmful drug pricing policies with complete disregard for the negative impact they will have on patients and our economy. At the same time, they are continuing to...   Read More

340B program remains second largest federal drug program, yet little solid evidence of benefits to patient

By Nicole Longo  |    June 30, 2022
Over the three decades since Congress created the 340B drug pricing program, we’ve seen massive growth in its size. As a program meant to serve vulnerable patients, this sounds great, right? The...   Read More

Study after study after study: Contract pharmacy expansion not aligned in communities 340B is meant to serve

By Nicole Longo  |    June 24, 2022
Evidence continues to show that 340B hospitals and their contract pharmacies are often not helping patients access their medicines, especially patients in socioeconomically disadvantaged areas....   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."